Christian Schetter
Vorsitzender bei STipe Therapeutics ApS
Profil
Christian Schetter is currently the Executive Chairman at STipe Therapeutics ApS, Independent Director at OMEICOS Therapeutics GmbH, and a Member of the Management Board at BIO Deutschland.
He previously served as the President & CEO at Neovii Biotech GmbH from 2008 to 2014, CEO & Member of the Supervisory Board at Rigontec GmbH from 2015 to 2018, Senior VP & Managing Director at Coley Pharmaceutical GmbH, and Senior VP-European Operations at Coley Pharmaceutical Group, Inc. He also served as a Director at Aura Biosciences, Inc. and Pyxis Oncology, Inc. and briefly as the Managing Director at Arix Bioscience Plc and Director at Twelve Bio.
Dr. Schetter received his undergraduate and doctorate degrees from Universität zu Köln.
Aktive Positionen von Christian Schetter
| Unternehmen | Position | Beginn |
|---|---|---|
BIO Deutschland
 BIO Deutschland Miscellaneous Commercial ServicesCommercial Services BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006. | Corporate Officer/Principal | - |
OMEICOS Therapeutics GmbH
 OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Direktor/Vorstandsmitglied | 11.02.2019 |
STipe Therapeutics ApS
 STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Vorsitzender | 30.09.2019 |
Ehemalige bekannte Positionen von Christian Schetter
| Unternehmen | Position | Ende |
|---|---|---|
| ARIX BIOSCIENCE PLC | Corporate Officer/Principal | 31.08.2021 |
Twelve Bio
 Twelve Bio Miscellaneous Commercial ServicesCommercial Services Part of Ensoma, Inc., Twelve Bio is a Danish company that seeks to expand the breadth of CRISPR-based gene-editing medicines to transform the management of serious diseases. The company is based in Copenhagen, Denmark. Twelve Bio uses its insights into nuclease structure and function to design highly precise and nimble CRISPR-Cas12 candidates for therapeutic application. The company will continuously advance its platform and understanding of Cas enzymes to address the needs of patients worldwide. The company was founded by Stefano Stella, Guillermo Montoya. Twelve Bio was acquired by Ensoma, Inc. on February 09, 2023. | Vorsitzender | 17.06.2021 |
Rigontec GmbH
 Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Vorstandsvorsitzender | 31.12.2018 |
Neovii Biotech GmbH
 Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Vorstandsvorsitzender | 01.01.2014 |
Coley Pharmaceutical Group, Inc.
 Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Corporate Officer/Principal | 03.05.2011 |
Ausbildung von Christian Schetter
| Universität zu Köln | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Health Technology |
Coley Pharmaceutical GmbH
 Coley Pharmaceutical GmbH Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Coley Pharmaceutical GmbH is a German company that provides research and development in the field of natural sciences, engineering, agricultural sciences and medicine. The company is based in Berlin, Germany. The company was founded by Heather L. Davis. | Commercial Services |
BIO Deutschland
BIO Deutschland Miscellaneous Commercial ServicesCommercial Services BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006. | Commercial Services |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
Rigontec GmbH
Rigontec GmbH Pharmaceuticals: MajorHealth Technology Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany. | Health Technology |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Health Technology |
Twelve Bio
Twelve Bio Miscellaneous Commercial ServicesCommercial Services Part of Ensoma, Inc., Twelve Bio is a Danish company that seeks to expand the breadth of CRISPR-based gene-editing medicines to transform the management of serious diseases. The company is based in Copenhagen, Denmark. Twelve Bio uses its insights into nuclease structure and function to design highly precise and nimble CRISPR-Cas12 candidates for therapeutic application. The company will continuously advance its platform and understanding of Cas enzymes to address the needs of patients worldwide. The company was founded by Stefano Stella, Guillermo Montoya. Twelve Bio was acquired by Ensoma, Inc. on February 09, 2023. | Commercial Services |
Neovii Biotech GmbH
Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | Health Technology |
